Agenus To Present Data On Botensilimab And AGEN1721 At SITC 2024; Novel Candidates Show Promise In Turning Cold And Refractory Tumors Into Responsive Targets
Agenus To Present Data On Botensilimab And AGEN1721 At SITC 2024; Novel Candidates Show Promise In Turning Cold And Refractory Tumors Into Responsive Targets
Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets
新型候选药物展示出将冷漠和难治性肿瘤转变为可响应靶点的潜力
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus.
艾吉纳斯公司（"艾吉纳斯"）（纳斯达克：AGEN），是一家致力于开发新型免疫药物治疗各种癌症的领军企业，今天宣布了其两个有前景的候选免疫治疗药物博特尼利单抗和AGEN1721的最新数据，将在德克萨斯州休斯顿举行的海丰国际免疫疗法协会2024年年会上展示。这些数据展示了在治疗免疫耐药肿瘤方面潜在的突破，将由艾吉纳斯公司研究副总裁达恩·钱德博士（Dhan Chand, Ph.D.）进行介绍。
